anlotinib + bevacizumab

Anlotinib + bevacizumab is a combination therapy consisting of two antiangiogenic agents used primarily in the treatment of recurrent high-grade glioma (rHGG) and recurrent glioblastoma (GBM). Anlotinib is an oral small-molecule multi-target tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and c-Kit, thereby inhibiting tumor angiogenesis and proliferation. Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), preventing its interaction with VEGF receptors on the surface of endothelial cells, thus inhibiting angiogenesis. The combination leverages dual antiangiogenic mechanisms—anlotinib’s inhibition of multiple receptor tyrosine kinases involved in angiogenesis and bevacizumab’s direct neutralization of VEGF-A—to enhance antitumor efficacy. This regimen has shown promising results in clinical studies for rHGG/GBM, with manageable safety profiles[1][2].